Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Marinus Pharmaceuticals Inc's Business Segments
Marinus Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 9
Regions Reported
-
Marinus Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product99.1%
- Collaboration Revenue0.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 8 | 99.1% |
| Collaboration Revenue | $ 0 | 0.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics to treat rare seizure disorders and neuropsychiatric disorders. The company specializes in the development of drugs that target the GABA system, a key neurotransmitter system involved in regulating brain activity.
Marinus Pharmaceuticals was founded in 2003 and is headquartered in Radnor, Pennsylvania. The company's main product candidate is ganaxolone, a synthetic analog of allopregnanolone, an endogenous neuroactive steroid that acts as a positive allosteric modulator of the GABA-A receptor. Ganaxolone is believed to enhance the signaling of the inhibitory neurotransmitter GABA, which helps to reduce excitability and regulate neuronal activity in the brain.
The primary focus of Marinus Pharmaceuticals is on developing ganaxolone as a potential treatment for several rare seizure disorders and neuropsychiatric conditions, including:
1. CDKL5 Deficiency Disorder (CDD): CDD is a rare genetic disorder characterized by early-onset seizures, developmental delays, and intellectual disabilities. There are currently no approved treatments for CDD, and ganaxolone is being investigated as a potential therapy to reduce seizure frequency and improve cognitive function in these patients.
2. PCDH19-related Epilepsy: PCDH19-related epilepsy is another rare genetic disorder that primarily affects females. It is characterized by early-onset seizures and cognitive impairments. Marinus Pharmaceuticals is developing ganaxolone as a potential treatment for reducing seizure frequency and improving cognitive function in these patients.
3. Fragile X Syndrome (FXS): FXS is a genetic disorder that causes intellectual disabilities, behavioral challenges, and seizures. Marinus Pharmaceuticals is investigating ganaxolone as a potential therapy to reduce seizure frequency and improve behavior and cognitive function in individuals with FXS.
4. Postpartum Depression (PPD): Marinus Pharmaceuticals is also exploring the potential of ganaxolone as a treatment for women with PPD, a mood disorder that affects approximately 1 in 7 women after childbirth. Ganaxolone's mechanism of action, targeting GABA receptors, is believed to have an impact on the regulation of mood and anxiety.
In addition to its ongoing clinical trials, Marinus Pharmaceuticals has also conducted preclinical research to explore the potential of ganaxolone in other indications, such as acute and chronic pain conditions, cranial trauma, and epilepsy associated with other rare genetic disorders.
The company has a dedicated team of scientists, researchers, and clinicians who work collaboratively to advance the development of ganaxolone and other potential therapies. They conduct rigorous clinical trials to assess drug safety, efficacy, and tolerability, as well as engage in partnerships with academic institutions, patient advocacy groups, and regulatory authorities to further their research and advancement in the field.
Marinus Pharmaceuticals has received orphan drug designations from the U.S. Food and Drug Administration (FDA) for ganaxolone in multiple indications, providing various regulatory and financial incentives to support the development and commercialization of the drug. Additionally, the company has secured grants and funding from organizations such as the National Institutes of Health (NIH) and the Epilepsy Foundation to further its research efforts.
Overall, Marinus Pharmaceuticals Inc. is a pioneering biopharmaceutical company, dedicated to addressing significant unmet medical needs in rare seizure disorders and neuropsychiatric conditions through the development and commercialization of innovative therapies such as ganaxolone.
Marinus Pharmaceuticals was founded in 2003 and is headquartered in Radnor, Pennsylvania. The company's main product candidate is ganaxolone, a synthetic analog of allopregnanolone, an endogenous neuroactive steroid that acts as a positive allosteric modulator of the GABA-A receptor. Ganaxolone is believed to enhance the signaling of the inhibitory neurotransmitter GABA, which helps to reduce excitability and regulate neuronal activity in the brain.
The primary focus of Marinus Pharmaceuticals is on developing ganaxolone as a potential treatment for several rare seizure disorders and neuropsychiatric conditions, including:
1. CDKL5 Deficiency Disorder (CDD): CDD is a rare genetic disorder characterized by early-onset seizures, developmental delays, and intellectual disabilities. There are currently no approved treatments for CDD, and ganaxolone is being investigated as a potential therapy to reduce seizure frequency and improve cognitive function in these patients.
2. PCDH19-related Epilepsy: PCDH19-related epilepsy is another rare genetic disorder that primarily affects females. It is characterized by early-onset seizures and cognitive impairments. Marinus Pharmaceuticals is developing ganaxolone as a potential treatment for reducing seizure frequency and improving cognitive function in these patients.
3. Fragile X Syndrome (FXS): FXS is a genetic disorder that causes intellectual disabilities, behavioral challenges, and seizures. Marinus Pharmaceuticals is investigating ganaxolone as a potential therapy to reduce seizure frequency and improve behavior and cognitive function in individuals with FXS.
4. Postpartum Depression (PPD): Marinus Pharmaceuticals is also exploring the potential of ganaxolone as a treatment for women with PPD, a mood disorder that affects approximately 1 in 7 women after childbirth. Ganaxolone's mechanism of action, targeting GABA receptors, is believed to have an impact on the regulation of mood and anxiety.
In addition to its ongoing clinical trials, Marinus Pharmaceuticals has also conducted preclinical research to explore the potential of ganaxolone in other indications, such as acute and chronic pain conditions, cranial trauma, and epilepsy associated with other rare genetic disorders.
The company has a dedicated team of scientists, researchers, and clinicians who work collaboratively to advance the development of ganaxolone and other potential therapies. They conduct rigorous clinical trials to assess drug safety, efficacy, and tolerability, as well as engage in partnerships with academic institutions, patient advocacy groups, and regulatory authorities to further their research and advancement in the field.
Marinus Pharmaceuticals has received orphan drug designations from the U.S. Food and Drug Administration (FDA) for ganaxolone in multiple indications, providing various regulatory and financial incentives to support the development and commercialization of the drug. Additionally, the company has secured grants and funding from organizations such as the National Institutes of Health (NIH) and the Epilepsy Foundation to further its research efforts.
Overall, Marinus Pharmaceuticals Inc. is a pioneering biopharmaceutical company, dedicated to addressing significant unmet medical needs in rare seizure disorders and neuropsychiatric conditions through the development and commercialization of innovative therapies such as ganaxolone.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing innovative therapies for patients with severe neuropsychiatric disorders, particularly those involving epilepsy. The companys primary area of expertise lies in harnessing the therapeutic potential of cannabinoids, specifically its lead product designed to address conditions associated with epilepsy and other neurological disorders.
Segments
1. Epilepsy Treatment:
- Focus on Rare Epilepsy: Marinus Pharmaceuticals is particularly focused on developing treatments for rare and severe forms of epilepsy, which often have limited treatment options. Their approach involves both investigational and approved medications that leverage their experience with cannabinoid-based therapies.
2. Broad Neurological Disorders:
- While the primary focus is on epilepsy, Marinus is also exploring how their therapies can impact other neurological disorders, reflecting a broader commitment to neuropsychiatric health.
3. Research and Development:
- Engaging in extensive research initiatives, Marinus aims to uncover new indications for existing products and to develop next-generation cannabinoid therapeutics. They invest in clinical trials and studies to validate their hypotheses and expand their therapeutic footprint.
Products
1. Ganaxolone:
- The lead product of Marinus Pharmaceuticals, ganaxolone, is an investigational drug designed for the treatment of various epilepsy syndromes.
- Mechanism of Action: Ganaxolone is a neuroactive steroid that modulates the GABA-A receptor, and it is aimed at providing relief from seizures while minimizing side effects associated with traditional antiepileptic drugs.
- Indications: The product is being evaluated for several epilepsy-related conditions, which may include Dravet syndrome and other refractory epilepsy disorders.
2. Product Pipeline:
- Ganaxolone is part of a larger pipeline of potential pharmaceutical products under development. This pipeline includes additional cannabinoid derivatives, each focusing on optimizing efficacy and safety profiles across diverse neurological conditions.
- The company constantly explores combinations or novel formulations to enhance therapeutic outcomes across various patient demographics.
Services
1. Clinical Trials:
- Marinus Pharmaceuticals conducts comprehensive clinical trials to evaluate the safety and efficacy of ganaxolone and other products. Participating in these trials is crucial for obtaining regulatory approvals and advancing their products to market.
2. Patient Support Initiatives:
- The company offers educational resources and support services for patients and caregivers affected by epilepsy and other neurological disorders. This includes information on managing conditions, understanding treatment options, and establishing connections with healthcare professionals.
3. Collaborative Research:
- Marinus engages in partnerships with academic institutions and research organizations to facilitate studies related to cannabinoid therapies and their impact on various neurological conditions. This collaborative approach helps in generating robust data that can lead to new therapeutic insights.
4. Regulatory Affairs:
- The company helps navigate the complex landscape of regulatory approvals, working closely with agencies like the FDA to bring innovative therapies to market. This includes managing submissions for Investigational New Drug (IND) applications and New Drug Applications (NDA).
By concentrating on neuroactive steroid therapies, particularly in the realm of epilepsy, Marinus Pharmaceuticals is positioned to offer significant advancements in treatment options that address unmet medical needs. The synergy between their research initiatives, clinical development pathway, and patient support services underlines their commitment to improving the quality of life for those affected by severe neuropsychiatric disorders.
Segments
1. Epilepsy Treatment:
- Focus on Rare Epilepsy: Marinus Pharmaceuticals is particularly focused on developing treatments for rare and severe forms of epilepsy, which often have limited treatment options. Their approach involves both investigational and approved medications that leverage their experience with cannabinoid-based therapies.
2. Broad Neurological Disorders:
- While the primary focus is on epilepsy, Marinus is also exploring how their therapies can impact other neurological disorders, reflecting a broader commitment to neuropsychiatric health.
3. Research and Development:
- Engaging in extensive research initiatives, Marinus aims to uncover new indications for existing products and to develop next-generation cannabinoid therapeutics. They invest in clinical trials and studies to validate their hypotheses and expand their therapeutic footprint.
Products
1. Ganaxolone:
- The lead product of Marinus Pharmaceuticals, ganaxolone, is an investigational drug designed for the treatment of various epilepsy syndromes.
- Mechanism of Action: Ganaxolone is a neuroactive steroid that modulates the GABA-A receptor, and it is aimed at providing relief from seizures while minimizing side effects associated with traditional antiepileptic drugs.
- Indications: The product is being evaluated for several epilepsy-related conditions, which may include Dravet syndrome and other refractory epilepsy disorders.
2. Product Pipeline:
- Ganaxolone is part of a larger pipeline of potential pharmaceutical products under development. This pipeline includes additional cannabinoid derivatives, each focusing on optimizing efficacy and safety profiles across diverse neurological conditions.
- The company constantly explores combinations or novel formulations to enhance therapeutic outcomes across various patient demographics.
Services
1. Clinical Trials:
- Marinus Pharmaceuticals conducts comprehensive clinical trials to evaluate the safety and efficacy of ganaxolone and other products. Participating in these trials is crucial for obtaining regulatory approvals and advancing their products to market.
2. Patient Support Initiatives:
- The company offers educational resources and support services for patients and caregivers affected by epilepsy and other neurological disorders. This includes information on managing conditions, understanding treatment options, and establishing connections with healthcare professionals.
3. Collaborative Research:
- Marinus engages in partnerships with academic institutions and research organizations to facilitate studies related to cannabinoid therapies and their impact on various neurological conditions. This collaborative approach helps in generating robust data that can lead to new therapeutic insights.
4. Regulatory Affairs:
- The company helps navigate the complex landscape of regulatory approvals, working closely with agencies like the FDA to bring innovative therapies to market. This includes managing submissions for Investigational New Drug (IND) applications and New Drug Applications (NDA).
By concentrating on neuroactive steroid therapies, particularly in the realm of epilepsy, Marinus Pharmaceuticals is positioned to offer significant advancements in treatment options that address unmet medical needs. The synergy between their research initiatives, clinical development pathway, and patient support services underlines their commitment to improving the quality of life for those affected by severe neuropsychiatric disorders.